Company: INGN
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0000950170-25-045737
Chunk: 59

Company: Inogen Inc
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 59
---
 required by the applicable requirements of the PCAOB regarding Deloitte & Touche LLP’s communications with the Audit Committee concerning independence, and has discussed with Deloitte & Touche LLP its tenure and independence.

Based on the review and discussions referred to above, the Audit Committee recommended to the Board that the Company’s Audited Financial Statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC. The Audit Committee also has selected Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025. The Board recommends that stockholders ratify this selection at the Annual Meeting.

Respectfully submitted by the members of the Audit Committee of the Board of Directors:

Glenn Boehnlein (Chairperson)

Kevin King

Mary Katherine Ladone

<div align='center'>-38-

EXECUTIVEOFFICERS</div>

The following table identifies certain information about our executive officers as of March 17, 2025. Each executive officer serves at the discretion of our Board and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers.

| Name             |     | Age |     | Position(s)                                                                 |
| Kevin R.M. Smith |     |  54 |     | Chief Executive Officer, President and Director                             |
| Michael Bourque  |     |  62 |     | Executive Vice President, Chief Financial Officer, and Corporate Treasurer  |
| Kevin P. Smith   |     |  54 |     | Executive Vice President, General Counsel, Secretary & Business Development |
| Gregoire Ramade  |     |  55 |     | Executive Vice President, Chief Commercial Officer                          |

Kevin R. M. Smithhas served as our Chief Executive Officer, President and a member of our Board since November 2023. Prior to joining Inogen, Mr. Smith served as the CEO, President and Executive Director at Sirtex Medical Limited, a medical device company, from April 2019 to November 2023, after serving as Executive Vice President of Sales & Marketing, Americas from 2017 to 2019. Mr. Smith also served on Sirtex's Board of Directors from 2019 to 2023. From December 2021 to April 2022, Mr. Smith also served as interim President and Chief Executive Officer and Director at